CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 75-95% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Zura Bio Provides Clinical Update on Phase 2 Study of Tibulizumab in Hidradenitis Suppurativa

By Reuters News

Nov 9 (Reuters) - Zura Bio Ltd ZURA.O:

  • ZURA BIO PROVIDES CLINICAL UPDATE ON PHASE 2 TIBUSHIELD STUDY OF TIBULIZUMAB (ZB-106) IN HIDRADENITIS SUPPURATIVA

  • ZURA BIO - DISCONTINUES DEVELOPMENT OF TIBULIZUMAB IN HIDRADENITIS SUPPURATIVA

  • ZURA BIO LTD: STUDY DID NOT MEET PRIMARY ENDPOINT

  • ZURA BIO - TIBULIZUMAB WELL TOLERATED WITH SAFETY CONSISTENT WITH IL-17 AND BAFF INHIBITION PROFILES

  • ZURA BIO - EXPECTS CASH SUFFICIENT FOR OPERATIONS THROUGH END OF 2028

  • ZURA BIO LTD: KEY SECONDARY ENDPOINTS, INCLUDING HISCR50 AND HISCR75, WERE ALSO NOT MET.

Further company coverage: ZURA.O

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.